Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.68 |
| ▸ | LOX | P28300 | 2/20 | 0.68 |
| ▸ | IDO1 | P14902 | 15/20 | 0.49 |
| ▸ | AGXT | P21549 | 11/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2092744 | 0.85 | LOXL2 (0.67) | LOXL2LOX | |
| SCHEMBL2092739 | 0.81 | LOXL2 (0.62) | LOXL2LOX | |
| SCHEMBL449200 | 0.81 | LOXL2 (1.00) | LOXL2LOX | |
| Hydrochloric Acid SCHEMBL463199 | 0.79 | LOXL2 (0.96) | LOXL2LOX | |
| SCHEMBL4018107 | 0.79 | LOXL2 (0.59) | LOXL2LOX | |
| SCHEMBL19251359 | 0.79 | LOXL2 (0.59) | LOXL2LOX | |
| SCHEMBL805488 | 0.79 | LOXL2 (0.69) | LOXL2LOX | |
| SCHEMBL6218599 | 0.78 | LOXL2 (0.73) | LOXL2LOXCYP3A4 | |
| SCHEMBL130180 | 0.77 | LOXL2 (0.67) | LOXL2LOX | |
| SCHEMBL2224895 | 0.77 | LOXL2 (0.67) | LOXL2LOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | LOXL2 593/4885LOX 570/4885IDO1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.